Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study compared the effect of indacaterol (300 μg once daily [od]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
Status | Completed |
Enrollment | 90 |
Est. completion date | January 2009 |
Est. primary completion date | January 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Male and female adults aged = 40 years, who have signed an informed consent form prior to initiation of any study-related procedure. - Co-operative outpatients with a diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD), as classified by the GOLD Guidelines (2006), and: - Smoking history of at least 20 pack years. - Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and = 30% of the predicted normal value. - Post-bronchodilator FEV1/forced vital capacity (FVC) < 70%. Exclusion Criteria: - Pregnant or nursing (lactating) women. - Women of child-bearing potential. - Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period. - Patients requiring oxygen therapy or who experience oxygen desaturation to < 80% during cycle exercise on room air. - Patients with a Wmax value < 20 W (as determined by the incremental cycle endurance test) at screening. - Patients who have had a respiratory tract infection within 6 weeks prior to screening. - Patients with contra-indications of cardiopulmonary exercise testing. - Patients with concomitant pulmonary disease. - Patients with a history (up to and including the screening visit) of asthma. - Patients with diabetes Type I or uncontrolled diabetes Type II. - Any patient with lung cancer or a history of lung cancer. - Any patient with active cancer or a history of cancer with less than 5 years disease free survival time. - Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at the collection of informed consent visit (Visit 1) or randomization is prolonged. - Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period. - Patients unable to successfully use a dry powder inhaler device, metered dose inhaler (MDI), or perform spirometry measurements. Other protocol-defined inclusion/exclusion criteria applied to the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Novartis Investigator Site | Bruxelles | |
Belgium | Novartis Investigator Site | Gembloux | |
Belgium | Novartis Investigator Site | Jette | |
Belgium | Novartis Investigator Site | Liege | |
Canada | Novartis Investigator Site | Edmonton | |
Canada | Novartis Investigator Site | Kingston | |
Denmark | Novartis Investigator Site | Aarhus | |
Denmark | Novartis Investigative Site | Hellerup | |
Denmark | Novartis Investigator Site | Hvidovre | |
Denmark | Novartis Investigative site | Odense | |
Italy | Novartis Investigator Site | Genova | |
Italy | Novartis Investigator Site | Pisa | |
Italy | Novartis Investigator Site | Verona | |
Spain | Novartis Investigator Site | Alicante | |
Spain | Novartis Investigator Site | Barcelona | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative site | Seville | |
Spain | Novartis Investigator Site | Zaragoza | |
United States | Novartis Investigator Site | Lebanon | New Hampshire |
United States | Novartis Investigator Site | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Novartis |
United States, Belgium, Canada, Denmark, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise Duration Time Assessed by Constant-load Cycle Ergometry at the End of Each Treatment Period | At the end of each 3 week treatment period, patients completed constant-load cycle ergometry testing at a work-rate of 75% of the Wmax determined at Screening. This work-rate was maintained until symptom limitation caused the patient to stop exercising. The time from the start of loaded pedaling until the patient stopped exercising was recorded. | End of each 3 week treatment period (last day of Weeks 3 and 9) | No |
Secondary | Inspiratory Capacity (IC) Assessed at Rest With Spirometry at the End of Each Treatment Period 60 Minutes Pre-dose | At the end of each 3 week treatment period 60 minutes before inhalation of study drug, IC was measured with spirometry conducted according to internationally accepted standards. The mean of 3 acceptable measurements was calculated and reported in liters. | End of each 3 week treatment period (last day of Weeks 3 and 9) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|